• Consensus Rating: Buy
  • Consensus Price Target: C$8.00
  • Forecasted Upside: 2.56 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$7.80
▲ +0.01 (0.13%)

This chart shows the closing price for RX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioSyent Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RX

Analyst Price Target is C$8.00
▲ +2.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioSyent in the last 3 months. The average price target is C$8.00, with a high forecast of C$0.00 and a low forecast of C$0.00. The average price target represents a 2.56% upside from the last price of C$7.80.

This chart shows the closing price for RX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in BioSyent. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/10/2022Bloom BurtonUpgradeHold ➝ Accumulate
3/10/2022Raymond JamesBoost Price TargetMarket PerformC$7.50 ➝ C$8.00
11/19/2021Raymond JamesSet Price TargetMarket PerformC$7.50
8/26/2021Raymond JamesSet Price TargetMarket PerformC$7.50
5/28/2021Raymond JamesBoost Price TargetMarket PerformC$7.00 ➝ C$7.50
3/18/2021Bloom BurtonDowngradeAccumulate ➝ Hold
3/18/2021Raymond JamesSet Price TargetMarket PerformC$7.00
11/28/2020Raymond JamesSet Price TargetMarket PerformC$7.00
10/2/2020Raymond JamesBoost Price TargetMarket PerformC$6.00 ➝ C$7.00
8/27/2020Raymond JamesDowngradeOutperform ➝ Market PerformC$6.00
5/29/2020Raymond JamesSet Price TargetOutperformC$6.00
3/19/2020Bloom BurtonDowngradeBuy ➝ Accumulate
3/19/2020Raymond JamesUpgradeMarket Perform ➝ OutperformC$6.50 ➝ C$6.00
11/27/2019Raymond JamesSet Price TargetMarket PerformC$6.50
11/21/2019Raymond JamesSet Price TargetMarket PerformC$6.50
8/26/2019Bloom BurtonUpgradeAccumulate ➝ Buy
8/26/2019Raymond JamesLower Price TargetMarket PerformC$7.50 ➝ C$6.00
8/26/2019CormarkLower Price TargetC$8.25 ➝ C$7.50
6/27/2019Raymond JamesDowngradeOutperform ➝ Market PerformC$9.50 ➝ C$7.50
5/30/2019Raymond JamesLower Price TargetOutperformC$10.00 ➝ C$9.50
5/15/2019Raymond JamesSet Price TargetOutperformC$10.00
3/27/2019Raymond JamesLower Price TargetOutperformC$11.00 ➝ C$10.00
3/21/2019Raymond JamesSet Price TargetOutperformC$11.00
11/22/2018Raymond JamesLower Price TargetOutperformC$12.50 ➝ C$11.00
5/1/2018Raymond JamesSet Price TargetOutperformC$12.50
3/22/2018Bloom BurtonReiterated RatingAccumulate
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/3/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BioSyent logo
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: C$7.80
Low: C$7.79
High: C$7.88

50 Day Range

MA: C$8.37
Low: C$7.66
High: C$9.35

52 Week Range

Now: C$7.80
Low: C$6.76
High: C$10.00

Volume

52,418 shs

Average Volume

4,064 shs

Market Capitalization

C$96.78 million

P/E Ratio

16.12

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BioSyent?

The following equities research analysts have issued research reports on BioSyent in the last twelve months: Bloom Burton, and Raymond James.
View the latest analyst ratings for RX.

What is the current price target for BioSyent?

0 Wall Street analysts have set twelve-month price targets for BioSyent in the last year. Their average twelve-month price target is C$8.00, suggesting a possible upside of 2.6%.
View the latest price targets for RX.

What is the current consensus analyst rating for BioSyent?

BioSyent currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RX will outperform the market and that investors should add to their positions of BioSyent.
View the latest ratings for RX.

How do I contact BioSyent's investor relations team?

BioSyent's physical mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company's listed phone number is +1-905-2060013. The official website for BioSyent is www.biosyent.com. Learn More about contacing BioSyent investor relations.